Literature DB >> 32387762

Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: Case report.

Yildiz Kaya1, Simay Kara2, Canan Akinci3, Ayse Sagduyu Kocaman4.   

Abstract

Entities:  

Keywords:  Covid-19; Neurological involvement; PRES like syndrome

Mesh:

Year:  2020        PMID: 32387762      PMCID: PMC7187859          DOI: 10.1016/j.jns.2020.116858

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


× No keyword cloud information.
Dear Editor, The World Health Organization declared the outbreak of the 2019 novel coronavirus, in March 12th, 2020, a global pandemic after widely spreading of the epidemic COVID-19 pneumonia cases [1]. It has been reported that, in addition to the respiratory tract infection symptoms, patients can also have neurologic signs and symptoms; like acute cerebrovascular disease, polyneuritis, encephalitis and encephalopathy [2]. In this report, we describe a patient who developed bilateral reversible cortical blindness, who presented by COVID-19 related pneumonia. A 38 years old male patient, admitted to emergency department with a history of fever for 5 days. His body temperature was 38,5 °C, blood pressure was 130/80 mmHg and oxygen saturation 98% while he was breathing ambient air. Breath sounds were normal with adventitious sounds on both sides. His chest computerised tomography (CT) scan showed multiple, multilobar, peripheral ground-glass opasifications in both lungs (Fig. 1 ). Laboratory tests results showed highly elevated CRP and ferritin levels with marked lymphopenia. His nasopharyngeal swab reverse transcription-PCR (RT-PCR) was positive for SARS-CoV-2. After admission, he received hydroxychloroquine (400 mg for the first day, 200 mg/day for four days), azitromicin 500 mg/day, and osetalmivir 150 mg/day combined with nasal oxygen therapy. His oxygen saturation was declined to 88% on the second day and non-invasive mechanical ventilatory support was started at intensive care unit (ICU). On the fifth day of ICU, he suddenly developed acute confusional state with agitation and his blood pressure observed to be at high levels for a few hours. Meanwhile, the patient complained about vision loss in both eyes. In his neurological examination; he was awake, but apathic and hardly obeying commands. His pupils were 2 mm and equally reactive to light. Fundus examination was normal. His visual acuity was severely impared on both eyes; he could only recognize waving hands and there was perception of light. His entire neurological examination was normal. Brain magnetic resonance imaging (MRI) showed bilateral, especially left occipital, frontal cortical white matter and splenium of corpus callosum T2/Fluid-attenuated inversion recovery (FLAIR) hyperintensities and diffusion restriction in diffusion weighted imaging (DWI) (Fig. 2 ) revealing vasogenic edema similar to posterior reversible leucoencephalopathy (PRES). Hydroxychloroquine treatment was stopped and the dexamethasone with a 24 mg/day dose is started. On second dose of corticosteroid treatment, patient was able to obey commands and his visual impairment fully recovered. In his neurocognitive assessment we determined visual agnosia which lasted in a week. The corticosteroid therapy tapered and stopped in two weeks' time. His neurological examination and neurocognitive assessment were completely normal on the tenth day. The brain MRI performed two weeks later, showed complete regression of the lesions (Fig. 3 ).
Fig. 1

Torax CT showed multiple, dominantly right patchy, peripheral, ground-glass opasities in both lungs a) coronal, b) Axial images.

Fig. 2

Brain diffusion weighted (DWI) MRI (a) showed bilateral, especially left occipital, frontal cortical white matter and splenium of corpus callosum diffusion restriction, (b) Apparent Diffusion Coefficient (ADC) showed reduced ADC values due to vasogenic edema and FLAIR sequences (c) showed hiperinteinsities in the same localizations.

Fig. 3

On the second week of therapy DWI (a), ADC (b) and FLAIR (c) sequences showed complete regression of the lesions.

Torax CT showed multiple, dominantly right patchy, peripheral, ground-glass opasities in both lungs a) coronal, b) Axial images. Brain diffusion weighted (DWI) MRI (a) showed bilateral, especially left occipital, frontal cortical white matter and splenium of corpus callosum diffusion restriction, (b) Apparent Diffusion Coefficient (ADC) showed reduced ADC values due to vasogenic edema and FLAIR sequences (c) showed hiperinteinsities in the same localizations. On the second week of therapy DWI (a), ADC (b) and FLAIR (c) sequences showed complete regression of the lesions.

Discussion

We still don't know why focal neurological deficits may arise during SARS-CoV-2 infection. Common suggestions for pathological mechanisms are direct virus infection invasion or inflamatory factors. Recent autopsy reports have revealed that, like many viral infections SARS-CoV-2 can cause brain tissue edema and partial neuronal degeneration [3]. Infectious toxic encephalopathy is a reversible brain dysfunction syndrome caused by systemic toxemia, metabolic disorders and hypoxia during the process of acute infection [4]. In this disease, main pathological change is brain edema without evidence of inflammation on cerebrospinal fluid analysis. Hypoxia in the brain causes anaerobic metabolism in the mitochondria of neurons and this leads cerebral vasodilatation, swelling of neurons, interstitial edema and obstruction of cerebral blood flow [5]. PRES is a result of a systemic inflammatory state causing endothelial dysfunction [6]. That hypothesis is supported by the observation that PRES is usually associated with a systemic inflammatory process such as sepsis, eclampsia, transplantation, and autoimmune disease [7]. Although we could not determine the exact ethiology in our case, regulating the blood pressure, controlling the vasogenic edema by corticosteroid treatment and controlling the virus related pneumonia have helped for the recovery of our patient. Unfortunately, evidences are lacking to determine which of these features were due to infectious toxic encephalopathy, and which features were specific to SARS-CoV-2 infection.

Declaration of Competing Interest

The authors declare that there are no competing interests associated with the manuscript.
  6 in total

Review 1.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 2.  [Interaction brain-lungs].

Authors:  L Abdennour; C Zeghal; M Dème; L Puybasset
Journal:  Ann Fr Anesth Reanim       Date:  2012-06-12

Review 3.  Encephalopathy of infection and systemic inflammation.

Authors:  G Bryan Young
Journal:  J Clin Neurophysiol       Date:  2013-10       Impact factor: 2.177

Review 4.  Posterior reversible encephalopathy syndrome.

Authors:  Marlene Fischer; Erich Schmutzhard
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

5.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

Review 6.  Nervous system involvement after infection with COVID-19 and other coronaviruses.

Authors:  Yeshun Wu; Xiaolin Xu; Zijun Chen; Jiahao Duan; Kenji Hashimoto; Ling Yang; Cunming Liu; Chun Yang
Journal:  Brain Behav Immun       Date:  2020-03-30       Impact factor: 7.217

  6 in total
  29 in total

Review 1.  MRI Brain Findings in 126 Patients with COVID-19: Initial Observations from a Descriptive Literature Review.

Authors:  E Gulko; M L Oleksk; W Gomes; S Ali; H Mehta; P Overby; F Al-Mufti; A Rozenshtein
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-03       Impact factor: 3.825

2.  EEG Abnormalities and Their Radiographic Correlates in a COVID-19 Inpatient Cohort.

Authors:  Sean T Hwang; Ahmad A Ballout; Anup N Sonti; Amitha Kapyur; Claudia Kirsch; Neeraj Singh; Noah Markowitz; Tung Ming Leung; Derek J Chong; Richard Temes; Steven V Pacia; Ruben I Kuzniecky; Souhel Najjar
Journal:  Neurol Clin Pract       Date:  2022-02

3.  Neurologic Findings Among Inpatients With COVID-19 at a Safety-net US Hospital.

Authors:  Pria Anand; Lan Zhou; Nahid Bhadelia; Davidson H Hamer; David M Greer; Anna M Cervantes-Arslanian
Journal:  Neurol Clin Pract       Date:  2021-04

Review 4.  Ocular Manifestations of Patients with Coronavirus Disease 2019: A Comprehensive Review.

Authors:  Amirhossein Roshanshad; Mohammad Ali Ashraf; Romina Roshanshad; Ali Kharmandar; Seyed Alireza Zomorodian; Hossein Ashraf
Journal:  J Ophthalmic Vis Res       Date:  2021-04-29

Review 5.  Posterior Reversible Encephalopathy Syndrome in Patients with Coronavirus Disease 2019: Two Cases and A Review of The Literature.

Authors:  Pria Anand; K H Vincent Lau; David Y Chung; Deepti Virmani; Anna M Cervantes-Arslanian; Asim Z Mian; Courtney E Takahashi
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-07-30       Impact factor: 2.136

6.  Botulism during SARS-CoV-2 pandemic: The importance of differential diagnoses.

Authors:  Antonio Gatto; Silvia Maria Pulitanò; Giorgio Conti; Paolo Maurizio Soave; Lorenzo Di Sarno; Antonio Chiaretti
Journal:  Anaerobe       Date:  2021-05-26       Impact factor: 3.331

7.  Response to correspondence concerning "Posterior reversible encephalopathy syndrome (PRES) associated with COVID-19".

Authors:  Sofia Lallana; James E Siegler
Journal:  J Clin Neurosci       Date:  2021-08-14       Impact factor: 1.961

8.  Neuroradiological Features of Mild and Severe SARS-CoV-2 Infection.

Authors:  Simon Pan; Willam C Chen; Joe D Baal; Leo P Sugrue
Journal:  Acad Radiol       Date:  2020-08-29       Impact factor: 3.173

9.  COVID-19-related intracranial imaging findings: a large single-centre experience.

Authors:  V Sawlani; S Scotton; K Nader; J P Jen; M Patel; K Gokani; P Denno; M Thaller; C Englezou; U Janjua; M Bowen; C Hoskote; T Veenith; G Hassan-Smith; S Jacob
Journal:  Clin Radiol       Date:  2020-09-15       Impact factor: 2.350

Review 10.  SARS-CoV-2 and the Nervous System: From Clinical Features to Molecular Mechanisms.

Authors:  Manuela Pennisi; Giuseppe Lanza; Luca Falzone; Francesco Fisicaro; Raffaele Ferri; Rita Bella
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.